entertainment -WSS

entertainment

author：hotspot 2025-09-30 17:28:17 - browse：5

Illustration of a prescription bottle image on the screen of a smart phone – medical tech coverage from STAT — Alex Hogan/STAT

In another sign of the business headwinds facing prescription mental health apps, developer Twill will shop around for a pharmaceutical company to market Aspiro, its cognitive behavioral therapy treatment for both generalized anxiety and major depression.

Twill executives told STAT the company hopes that a drugmaker developing or currently marketing a product for generalized anxiety, or GAD, and major depressive disorder, or MDD, will be interested in adding a digital therapeutic to boost the effect of its drug — as well as its sales. Twill’s chief strategy officer Chris Wasden said that after watching companies built around prescription digital therapeutics, or PDTs, stall out, Twill made the decision earlier this year that it would only take the product to market if it found a willing drugmaker to serve as its partner.

“A PDT is going to be more valuable in the hands of a drug company that has a drug that they would like to get greater adherence [and] greater revenues from rather than trying to get reimbursement for the PDT itself,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： What it’s like to watch children die of measles

hotspot

WSS

Just how do doctors, lawmakers, and the public define abortion?

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

IVF, abortion rights issues kick off Biden’s State of the Union

How to bring more disabled researchers into academia

Bristol Myers buys into radiopharmaceuticals with RayzeBio

How to bring more disabled researchers into academia

explore

entertainment

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Violet CEO on training clinicians to promote more inclusive care

23andMe had bad news about my health. I wish a person had delivered it

Virtual care provider acquires bankrupt Pear's prescription apps

Malaria cases in Florida and Texas: Here’s what you need to know

First medicine developed to treat MASH expected to be approved soon

As demand for Covid shots wanes, Moderna seeks its next success

Prime Medicine, Myeloid Therapeutics clash over genome

Duchenne breakthrough therapy leaves behind pioneering families

Why health records don't always know when patients are dead

entertainment

First medicine developed to treat MASH expected to be approved soon

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Amylyx ALS drug failure raises questions and concerns

Christmas in the PICU brings some surprising joy

Amylyx ALS drug failure raises questions and concerns

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

hotspot

focus

hotspot

focus